TB Alliance launched a webpage to provide information on national-level access to the BPaL regimen - a three-drug, 6-month, all-oral regimen composed of bedaquiline, pretomanid and linezolid for the treatment of highly drug-resistant forms of TB.
The tool can filter countries by region or the following access pathways:
- Regulatory approval
- Named Patient Access Program
- Global Drug Facility catalog of TB medicines
- Operational research
Explore the tool here.